Neuphoria Therapeutics (NEUP) Competitors $8.40 +0.20 (+2.44%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock NEUP vs. ABVC, ADVM, NRXP, ATRA, VTVT, ANL, ANVS, QNTM, ALGS, and KRONShould you be buying Neuphoria Therapeutics stock or one of its competitors? The main competitors of Neuphoria Therapeutics include ABVC BioPharma (ABVC), Adverum Biotechnologies (ADVM), NRx Pharmaceuticals (NRXP), Atara Biotherapeutics (ATRA), vTv Therapeutics (VTVT), Adlai Nortye (ANL), Annovis Bio (ANVS), Quantum Biopharma (QNTM), Aligos Therapeutics (ALGS), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry. Neuphoria Therapeutics vs. Its Competitors ABVC BioPharma Adverum Biotechnologies NRx Pharmaceuticals Atara Biotherapeutics vTv Therapeutics Adlai Nortye Annovis Bio Quantum Biopharma Aligos Therapeutics Kronos Bio ABVC BioPharma (NASDAQ:ABVC) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation. Which has more risk & volatility, ABVC or NEUP? ABVC BioPharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Do insiders and institutionals hold more shares of ABVC or NEUP? 11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 17.1% of ABVC BioPharma shares are owned by insiders. Comparatively, 0.7% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is ABVC or NEUP more profitable? Neuphoria Therapeutics has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. Neuphoria Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ABVC BioPharma-963.46% -29.62% -14.08% Neuphoria Therapeutics N/A N/A N/A Do analysts recommend ABVC or NEUP? Neuphoria Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 150.00%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, ABVC or NEUP? ABVC BioPharma has higher revenue and earnings than Neuphoria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioABVC BioPharma$510K108.21-$4.90M-$0.13-25.00Neuphoria Therapeutics$10K1,579.20-$15.49MN/AN/A Does the media refer more to ABVC or NEUP? In the previous week, ABVC BioPharma had 2 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for ABVC BioPharma and 1 mentions for Neuphoria Therapeutics. ABVC BioPharma's average media sentiment score of 0.99 beat Neuphoria Therapeutics' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Overall Sentiment ABVC BioPharma Positive Neuphoria Therapeutics Neutral SummaryNeuphoria Therapeutics beats ABVC BioPharma on 9 of the 14 factors compared between the two stocks. Get Neuphoria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEUP vs. The Competition Export to ExcelMetricNeuphoria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.42M$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E RatioN/A20.7327.9019.95Price / Sales1,579.20321.12442.19102.72Price / CashN/A43.2336.5558.97Price / Book0.538.308.635.90Net Income-$15.49M-$55.19M$3.24B$258.42M7 Day Performance12.15%5.07%3.22%1.94%1 Month Performance35.48%17.61%10.72%12.02%1 Year PerformanceN/A7.03%34.94%20.81% Neuphoria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEUPNeuphoria Therapeutics1.3394 of 5 stars$8.40+2.4%$21.00+150.0%N/A$15.42M$10K0.00N/APositive NewsHigh Trading VolumeABVCABVC BioPharma0.7027 of 5 stars$3.97+18.5%N/A+287.6%$56.89M$510K-30.5430High Trading VolumeADVMAdverum Biotechnologies4.1222 of 5 stars$2.54-6.6%$23.80+837.0%-65.6%$56.82M$1M-0.40190NRXPNRx Pharmaceuticals2.3789 of 5 stars$3.21-1.8%$28.50+787.9%+25.2%$56.54MN/A-1.602ATRAAtara Biotherapeutics4.6441 of 5 stars$9.23-2.6%$17.75+92.3%+17.5%$56.51M$128.94M-2.48330News CoveragePositive NewsInsider TradeGap UpVTVTvTv Therapeutics1.5991 of 5 stars$17.01-2.8%$35.50+108.7%-31.7%$55.90M$1.02M-5.659Positive NewsANLAdlai Nortye1.443 of 5 stars$1.61+6.6%$9.00+459.2%-58.4%$55.72M$5M0.00127Gap UpANVSAnnovis Bio2.2666 of 5 stars$2.72-4.6%$18.00+561.8%-75.2%$55.54MN/A-1.263News CoverageQNTMQuantum BiopharmaN/A$18.68-1.3%N/AN/A$55.01MN/A-1.17N/AALGSAligos Therapeutics3.7921 of 5 stars$8.36-4.9%$70.00+737.3%-32.5%$53.74M$3.94M-0.4890News CoverageGap DownKRONKronos BioN/A$0.88+1.5%$1.63+84.7%-35.8%$53.72M$9.85M-0.82100 Related Companies and Tools Related Companies ABVC Competitors ADVM Competitors NRXP Competitors ATRA Competitors VTVT Competitors ANL Competitors ANVS Competitors QNTM Competitors ALGS Competitors KRON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEUP) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEUP Stock Alerts